The global lung cancer liquid biopsy market accounted for USD 0.391 billion in 2023 and is expected to reach USD 3.19 billion by 2034 with a CAGR of 21.03% during the forecast period 2024-2034. The market will grow due to factors such as the rising incidence of lung cancer, the benefits of liquid biopsy over traditional techniques, the growing awareness and adoption of liquid biopsy, and the growing emphasis on personalized medicine.
The adoption of liquid biopsy in lung cancer diagnosis and treatment is anticipated to rise as more people become aware of its advantages. Leading medical organizations' recommendations and growing investments from biotechnology and pharmaceutical corporations in creating novel liquid biopsy tests are the driving forces behind this. For instance, in March 2024, Biocept and AstraZeneca announced a partnership to assess the DETECT test's ability to identify lung cancer patients who might benefit from tailored medicines.
By biomarker type, the circulating tumor DNA (ctDNA) segment accounted for the highest revenue-grossing segment in the global lung cancer liquid biopsy market in 2023 owing to its high sensitivity and specificity in detecting genetic mutations, early diagnosis capabilities, and utility in monitoring treatment response. For instance, Illumina, Inc. and Bristol Myers Squibb teamed up in 2022 to develop companion diagnostics for accurate oncology. Through technological advancements like the TSO 500 ctDNA liquid biopsy assay, which provides thorough genomic profiling to provide individualized treatment decisions, their partnership aims to improve therapy selection. Additionally, the exosomes segment is predicted to grow at the fastest CAGR during the forecast period owing to their potential in early cancer detection, real-time monitoring, and non-invasive nature.
By application, the non-small cell lung cancer segment accounted for the highest revenue-grossing segment in the global lung cancer liquid biopsy market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the high prevalence of the disease and the increasing adoption of targeted therapies. For instance, in August 2023: Guardant Health Results indicating the LUNAR test's capacity to identify minimum residual disease (MRD) in lung cancer patients following surgery was presented at the American Society of Clinical Oncology (ASCO) annual meeting. This could potentially improve patient monitoring and treatment choices.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global lung cancer liquid biopsy market in 2023 owing to the high volume of diagnostic procedures and the availability of advanced diagnostic technologies. For instance, in April 2024, the FDA approved Freenome Holdings' use of its ColonGuard test for patients 45 years of age and above, possibly expanding the target patient pool for early cancer diagnosis. Additionally, the diagnostic and imaging centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for specialized diagnostic services and the growing adoption of advanced imaging technologies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, high adoption of innovative technologies, and significant investment in cancer research. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of lung cancer, rising healthcare expenditure, and growing awareness about early cancer detection. For instance, Qiagen launched new QIAseq ctDNA Lung Panels in February 2024 that provide patients with lung cancer with thorough mutation profiling.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The adoption of liquid biopsy in lung cancer diagnosis and treatment is anticipated to rise as more people become aware of its advantages. Leading medical organizations' recommendations and growing investments from biotechnology and pharmaceutical corporations in creating novel liquid biopsy tests are the driving forces behind this. For instance, in March 2024, Biocept and AstraZeneca announced a partnership to assess the DETECT test's ability to identify lung cancer patients who might benefit from tailored medicines.
By biomarker type, the circulating tumor DNA (ctDNA) segment accounted for the highest revenue-grossing segment in the global lung cancer liquid biopsy market in 2023 owing to its high sensitivity and specificity in detecting genetic mutations, early diagnosis capabilities, and utility in monitoring treatment response. For instance, Illumina, Inc. and Bristol Myers Squibb teamed up in 2022 to develop companion diagnostics for accurate oncology. Through technological advancements like the TSO 500 ctDNA liquid biopsy assay, which provides thorough genomic profiling to provide individualized treatment decisions, their partnership aims to improve therapy selection. Additionally, the exosomes segment is predicted to grow at the fastest CAGR during the forecast period owing to their potential in early cancer detection, real-time monitoring, and non-invasive nature.
By application, the non-small cell lung cancer segment accounted for the highest revenue-grossing segment in the global lung cancer liquid biopsy market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the high prevalence of the disease and the increasing adoption of targeted therapies. For instance, in August 2023: Guardant Health Results indicating the LUNAR test's capacity to identify minimum residual disease (MRD) in lung cancer patients following surgery was presented at the American Society of Clinical Oncology (ASCO) annual meeting. This could potentially improve patient monitoring and treatment choices.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global lung cancer liquid biopsy market in 2023 owing to the high volume of diagnostic procedures and the availability of advanced diagnostic technologies. For instance, in April 2024, the FDA approved Freenome Holdings' use of its ColonGuard test for patients 45 years of age and above, possibly expanding the target patient pool for early cancer diagnosis. Additionally, the diagnostic and imaging centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for specialized diagnostic services and the growing adoption of advanced imaging technologies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, high adoption of innovative technologies, and significant investment in cancer research. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of lung cancer, rising healthcare expenditure, and growing awareness about early cancer detection. For instance, Qiagen launched new QIAseq ctDNA Lung Panels in February 2024 that provide patients with lung cancer with thorough mutation profiling.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Biomarker Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Lung Cancer Liquid Biopsy Market Report 2023 - 2034
Lung Cancer Liquid Biopsy Market Analysis & Forecast by Biomarker Type 2023 - 2034 (Revenue USD Bn)
- CTC (Circulating Tumor Cells)
- ctDNA (Circulating tumor DNA)
- Exosomes and RNA
Lung Cancer Liquid Biopsy Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
Lung Cancer Liquid Biopsy Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Diagnostic and Imaging Centres
- Hospitals
- Academic and Research Centers
- Others
Lung Cancer Liquid Biopsy Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Lung Cancer Liquid Biopsy Market: Biomarker Type Estimates & Trend Analysis
8. Lung Cancer Liquid Biopsy Market: Application Estimates & Trend Analysis
9. Lung Cancer Liquid Biopsy Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Lung Cancer Liquid Biopsy Market
12. Europe Global Lung Cancer Liquid Biopsy Market
13. Asia Pacific Global Lung Cancer Liquid Biopsy Market
14. Latin America Global Lung Cancer Liquid Biopsy Market
15. MEA Global Lung Cancer Liquid Biopsy Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Guardant Health Inc.
- Biocept Inc.
- Freenome Holdings Inc.
- Qiagen N.V.
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
- Illumina Inc.
- Roche Holding AG
- Grail Inc.
- Exact Sciences Corporation
- Natera Inc.
- Adaptive Biotechnologies Corporation
- Sysmex Corporation
- Personal Genome Diagnostics Inc.
- Inivata Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.39 Billion |
| Forecasted Market Value ( USD | $ 3.19 Billion |
| Compound Annual Growth Rate | 21.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
